Is Lisdexamfetamine Mesilate compatible with breastfeeding? Do we have alternatives for Lisdexamfetamine Mesilate?

Lisdexamfetamine Mesilate

September 2, 2017 (Low Risk)

A prodrug that is metabolized directly in the intestine to dextroamphetamine. It is used to treat Attention Deficit Hyperactivity Disorder (ADHD) and bulimia.

Dextroamfetamine is a sympathomimetic drug, central nervous system stimulant, whose action and uses are similar to amphetamine (see information) which is its dextro isomer.

It is excreted in breast milk, concentrating about 3 times more than in plasma and resulting in a relative dose of around 6% for the infant (Ilett, 2007).
In infants whose mothers were taking dexamfetamine as treatment for ADHD, levels ranging from undetectable to 14% of maternal plasma levels have been measured and no problems were observed in the clinical follow-up of these infants (Ilett, 2007).

There is little information on the impact of amphetamine abuse on infant development and health (Oei, 2012, Wise, 2007; Moretti, 2000), but it is known that they are more exposed to social problems, domestic violence, and lower rates of breastfeeding (Oei, 2010).

There is controversy over the possibly mild negative effect of amphetamine on prolactin (Petraglia, 1987; DeLeo, 1983), but milk production in mothers who took it therapeutically was not affected (Öhman, 2015).

During breastfeeding, the therapeutic use (ADHD, bulimia) of amphetamine can be assessed, using the lowest possible effective dose and monitoring the occurrence of irritability, insomnia, lack of appetite and weight loss.

Its use as an illegal drug is totally discouraged (Oei, 2012).


See below the information of this related product:

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Lisdexamfetamine dimesylate

Writings

  • Лисдексамфетамина Мезилат (Cyrillic)
  • リスデキサンフェタミンメシル酸塩 (Japanese)
  • Lisdexamfétamine Mésilate (French)
  • C15H25N3O,(CH4O3S)2 (Molecular formula)
  • (2S)-2,6-Diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate (Chemical name)

References

  1. AEMPS. Lisdexanfetamina. Ficha técnica. 2016 Full text (in our servers)
  2. Öhman I, Wikner BN, Beck O, Sarman I. Narcolepsy Treated with Racemic Amphetamine during Pregnancy and Breastfeeding. J Hum Lact. 2015Abstract
  3. Shire. Lisdexamfetamine. Drug Summary. 2013 Full text (in our servers)
  4. Oei JL, Kingsbury A, Dhawan A, Burns L, Feller JM, Clews S, Falconer J, Abdel-Latif ME. Amphetamines, the pregnant woman and her children: a review. J Perinatol. 2012Abstract Full text (link to original source) Full text (in our servers)
  5. Oei J, Abdel-Latif ME, Clark R, Craig F, Lui K. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child Fetal Neonatal Ed. 2010Abstract
  6. Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol. 2007Abstract
  7. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF; American Academy of Sleep Medicine. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007Abstract Full text (link to original source) Full text (in our servers)
  8. Moretti ME, Lee A, Ito S. Which drugs are contraindicated during breastfeeding? Practice guidelines. Can Fam Physician. 2000Abstract Full text (link to original source) Full text (in our servers)
  9. Petraglia F, De Leo V, Sardelli S, Mazzullo G, Gioffrè WR, Genazzani AR, D'Antona N. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women. Gynecol Obstet Invest. 1987Abstract
  10. DeLeo V, Cella SG, Camanni F, Genazzani AR, Müller EE. Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia. Horm Metab Res. 1983Abstract